Background: Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications. Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questions regarding effectiveness and durability of protection in routine clinical practice remain. We used Medicare data to investigate HZV effectiveness (VE) and its durability. Methods: This retrospective cohort study included beneficiaries ages ≥65 years during January 2007 through July 2014. Multiple adjustments to account for potential bias were made. HZV-vaccinated beneficiaries were matched to unvaccinated beneficiaries (primary analysis) and to HZV-unvaccinated beneficiaries who had received pneumococcal vaccination (secondary analysis). HZ outcomes in community and hospital settings were analyzed, including ophthalmic zoster (OZ) and postherpetic neuralgia (PHN). Results: Among eligible beneficiaries (average age 77 years), the primary analysis found VE for community HZ of 33% (95% CI: 32%-35%) and 19% (95% CI: 17%-22%), for the first 3, and subsequent 4+ years postvaccination, respectively. In the secondary analysis, VE was, respectively, 37% (95% CI: 36%-39%) and 22% (95% CI: 20%-25%). In the primary analysis, VE for PHN was 57% (95% CI: 52%-61%) and 45% (95% CI: 36%-53%) in the first 3 and subsequent 4+ years, respectively; VE for hospitalized HZ was, respectively, 74% (95% CI: 67%-79%) and 55% (95% CI: 39%-67%). Differences in VE by age group were not significant. Conclusions: In both the primary and secondary analyses, HZV provided protection against HZ across all ages, but effectiveness declined over time. VE was higher and better preserved over time for PHN and HZ-associated hospitalizations than for community HZ. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Background: Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications. Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questions regarding effectiveness and durability of protection in routine clinical practice remain. We used Medicare data to investigate HZV effectiveness (VE) and its durability. Methods: This retrospective cohort study included beneficiaries ages ≥65 years during January 2007 through July 2014. Multiple adjustments to account for potential bias were made. HZV-vaccinated beneficiaries were matched to unvaccinated beneficiaries (primary analysis) and to HZV-unvaccinated beneficiaries who had received pneumococcal vaccination (secondary analysis). HZ outcomes in community and hospital settings were analyzed, including ophthalmic zoster (OZ) and postherpetic neuralgia (PHN). Results: Among eligible beneficiaries (average age 77 years), the primary analysis found VE for community HZ of 33% (95% CI: 32%-35%) and 19% (95% CI: 17%-22%), for the first 3, and subsequent 4+ years postvaccination, respectively. In the secondary analysis, VE was, respectively, 37% (95% CI: 36%-39%) and 22% (95% CI: 20%-25%). In the primary analysis, VE for PHN was 57% (95% CI: 52%-61%) and 45% (95% CI: 36%-53%) in the first 3 and subsequent 4+ years, respectively; VE for hospitalized HZ was, respectively, 74% (95% CI: 67%-79%) and 55% (95% CI: 39%-67%). Differences in VE by age group were not significant. Conclusions: In both the primary and secondary analyses, HZV provided protection against HZ across all ages, but effectiveness declined over time. VE was higher and better preserved over time for PHN and HZ-associated hospitalizations than for community HZ. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Katia J Bruxvoort; Anna S Liang; Rafael Harpaz; Lei Qian; Lina S Sy; Philip LaRussa; D Scott Schmid; Yi Luo; Harpreet Takhar; Hung Fu Tseng Journal: Vaccine Date: 2019-05-11 Impact factor: 3.641
Authors: Yuwei Sun; Eric Kim; Christina L Kong; Benjamin F Arnold; Travis C Porco; Nisha R Acharya Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079
Authors: Anthony L Cunningham; Thomas C Heineman; Himal Lal; Olivier Godeaux; Roman Chlibek; Shinn-Jang Hwang; Janet E McElhaney; Timo Vesikari; Charles Andrews; Won Suk Choi; Meral Esen; Hideyuki Ikematsu; Martina Kovac Choma; Karlis Pauksens; Stéphanie Ravault; Bruno Salaun; Tino F Schwarz; Jan Smetana; Carline Vanden Abeele; Peter Van den Steen; Ilse Vastiau; Lily Yin Weckx; Myron J Levin Journal: J Infect Dis Date: 2018-05-05 Impact factor: 5.226
Authors: Nick Andrews; Julia Stowe; Galena Kuyumdzhieva; Bersabeh Sile; Ivelina Yonova; Simon de Lusignan; Mary Ramsay; Gayatri Amirthalingam Journal: BMJ Open Date: 2020-07-07 Impact factor: 2.692
Authors: Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz Journal: MMWR Morb Mortal Wkly Rep Date: 2018-01-26 Impact factor: 17.586
Authors: Jemma L Walker; Nick J Andrews; Gayatri Amirthalingam; Harriet Forbes; Sinead M Langan; Sara L Thomas Journal: Vaccine Date: 2018-03-17 Impact factor: 3.641